Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sickle Cell Gene Therapy May Need New US-Backed Payment Program, Grogan Suggests

Executive Summary

Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.

You may also be interested in...



Reality Check? Medicaid Costs From Cell, Gene Therapies Projected At (Just) $1Bn-$4Bn By 2030

Based on the current pipeline of durable therapies, MIT research indicates ‘it’s not a big lift to cover the children and the adults in Medicaid for these products,’ Mark Trusheim says.

Drug Pricing Reform In Medicaid: Watch This Space

Some manufacturers may have to start essentially paying Medicaid programs to cover their drugs beginning in 2024 under a provision in the US economic relief bill headed to President Biden. 

Calls For National Tech Assessment Program Could Be Amplified By Costs Of Cell, Gene Therapy

Speculation is growing that the Institute for Clinical and Economic Review or something like it could become the US version of the government-sponsored health tecnology assessment bodies in Europe.

Related Content

Topics

UsernamePublicRestriction

Register

PS142992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel